HER2-Positive Breast Cancer Market Report 2026

The her2-positive breast cancer market size has grown strongly in recent years. It will grow from $10.93 billion in 2025 to $11.7 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing identification of her2-positive cases, expansion of targeted oncology drug approvals, growth in hospital oncology infrastructure, availability of monoclonal antibody therapies, rising clinical trial activity.

The her2-positive breast cancer market size is expected to see strong growth in the next few years. It will grow to $15.23 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing adoption of next-generation her2 inhibitors, expansion of biosimilar penetration, growing demand for precision oncology treatments, rising investment in targeted cancer research, increasing focus on improving survival outcomes. Major trends in the forecast period include increasing adoption of her2-targeted antibody therapies, growing use of antibody-drug conjugates, expansion of companion diagnostic testing, rising focus on early-stage targeted treatment, enhanced integration of combination therapy approaches.

The strong adoption of immunotherapy is expected to drive the growth of the HER2-positive breast cancer market in the coming years. Immunotherapy is a medical treatment that enhances or modifies the immune system’s natural ability to fight diseases such as cancer, infections, and autoimmune disorders. Its adoption is attributed to its ability to improve the immune system’s recognition and elimination of cancer cells, providing higher efficacy and fewer side effects compared to conventional treatments. In HER2-positive breast cancer, immunotherapy enhances the body’s ability to identify and attack HER2-overexpressing cancer cells, improving treatment outcomes and reducing recurrence risk. For example, according to the American Association for Cancer Research, a US-based organization, the FDA approved 11 immune checkpoint inhibitors (ICIs) in 2023, with at least one ICI authorized for treating 20 different cancer types and any solid tumor exhibiting specific molecular characteristics. Therefore, widespread immunotherapy adoption is driving the HER2-positive breast cancer market.

Leading companies in the HER2-positive breast cancer market are developing innovative therapies, including HER2-directed antibody-drug conjugates (ADCs), to improve treatment precision and outcomes. HER2-directed ADCs combine an antibody specific to HER2 with a cytotoxic drug, delivering the drug directly to HER2-positive cancer cells for more effective therapy. For instance, in January 2024, AstraZeneca India Pharma Ltd., in collaboration with Daiichi Sankyo, launched Trastuzumab deruxtecan, a HER2-directed ADC that delivers a cytotoxic agent specifically to HER2-positive cells, offering a more targeted and effective treatment option.

In May 2023, Roche Holding AG, a Switzerland-based pharmaceutical company, acquired rights to Zion Pharma’s lead program, ZN-A-1041, for an undisclosed amount. The acquisition aims to advance the development and commercialization of ZN-A-1041, a blood-brain-barrier-penetrant HER2 inhibitor, for treating brain metastases in HER2-positive breast cancer patients. Zion Pharma Limited, a China-based biotechnology company, specializes in developing drugs for HER2-positive breast cancer.

Major companies operating in the her2-positive breast cancer market are F. Hoffmann-La Roche AG, AstraZeneca plc, Novartis International AG, Pfizer Inc., Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Daiichi Sankyo Co. Ltd., Takeda Pharmaceutical Company Limited, Bristol Myers Squibb, Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Seagen Inc., MacroGenics Inc., BioNTech SE, Incyte Corporation, Zymeworks Inc., Ambrx Biopharma Inc., Mersana Therapeutics Inc.

North America was the largest region in the HER2- positive breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the her2-positive breast cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the her2-positive breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the her2-positive breast cancer market by increasing costs of imported biologics, biosimilars, infusion devices, and advanced diagnostic reagents required for targeted therapy administration. Hospitals and oncology clinics in North America and Europe are most affected due to reliance on imported monoclonal antibodies and companion diagnostics, while Asia-Pacific faces pricing pressure on biologic imports. These tariffs are increasing treatment costs and impacting access in price-sensitive markets. At the same time, they are encouraging local biologics manufacturing, regional biosimilar development, and domestic production of oncology therapeutics.

The her2-positive breast cancer market research report is one of a series of new reports that provides her2-positive breast cancer market statistics, including her2-positive breast cancer industry global market size, regional shares, competitors with a her2-positive breast cancer market share, detailed her2-positive breast cancer market segments, market trends and opportunities, and any further data you may need to thrive in the her2-positive breast cancer industry. This her2-positive breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

HER2-positive breast cancer is a type of breast cancer characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2) protein, which promotes cancer cell growth. This form accounts for approximately 15-20% of breast cancers and is generally more aggressive than HER2-negative types, but it is treatable with targeted therapies that inhibit HER2 activity.

The main treatment options for HER2-positive breast cancer include targeted therapy, chemotherapy, endocrine therapy, immunotherapy, and other approaches. Targeted therapy is designed to specifically attack molecules, such as proteins or genes, that drive cancer growth, while minimizing damage to normal cells. These treatments are administered through various routes, including parenteral and oral, and are distributed via hospital pharmacies, retail pharmacies, and online pharmacies. End-users include hospitals, homecare settings, specialty clinics, and other healthcare providers.

The HER2-positive breast cancer market consists of sales of small molecule inhibitors, antibody-drug conjugates, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.